Justin Fowlkes, MD
Pulmonary Disease · Hammond, LANPI 1629392642
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,410 of the $11,612 with a category attached, or 63.8%. Intuitive Surgical accounts for 63.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $8,115 and has fallen 89.7% since, to $833 in 2025.
Across 238 payments — averaging $48.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- GSK$1K
- AstraZeneca$471
- Sanofi$322
- Boehringer Ingelheim$307
- Actelion Pharmaceuticals US, Inc.$229
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,20236%
- Education$7,41064%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $7,319 |
| GSK | 95 | $1,351 |
| AstraZeneca | 27 | $471 |
| Sanofi | 14 | $322 |
| Boehringer Ingelheim | 16 | $307 |
| Actelion Pharmaceuticals US, Inc. | 9 | $229 |
| Genentech USA, Inc. | 8 | $216 |
| Regeneron Healthcare Solutions, Inc. | 7 | $176 |
| United Therapeutics Corporation | 6 | $138 |
| Novartis | 7 | $125 |
| Abiomed | 2 | $115 |
| Grifols USA, LLC | 5 | $111 |
| Baxter Healthcare | 4 | $102 |
| Inari Medical, Inc. | 3 | $83 |
| Insmed, Inc. | 3 | $55 |
| Pulmonx Corporation | 1 | $50 |
| Astellas Pharma US Inc | 2 | $46 |
| Amgen | 2 | $45 |
| Verona Pharma, Inc. | 2 | $43 |
| Inogen, Inc. | 3 | $42 |
| Veran Medical Technologies, Inc. | 1 | $28 |
| Gilead | 2 | $27 |
| Advanced Respiratory, Inc | 1 | $26 |
| Fujifilm Sonosite, Inc. | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| Electromed, Inc. | 3 | $17 |
| Pfizer | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Resmed Corp | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,319
How this compares
$11,612 in reported general payments places this provider in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 555 | $419,265 |
| Breo ElliptaFluticasone/Vilanterol | 200 | $95,078 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $63,748 |
| Dupixent SyringeDupilumab | 14 | $54,620 |
| Spiriva RespimatTiotropium Bromide | 71 | $46,451 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $40,151 |
| EliquisApixaban | 50 | $37,992 |
| Spiriva HandihalerTiotropium Bromide | 45 | $33,053 |
| SymbicortBudesonide/Formoterol Fumarate | 109 | $30,423 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $22,002 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 773 | $20,064 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $15,663 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $13,025 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $12,574 |
| XareltoRivaroxaban | 14 | $9,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,351 | $576,496887 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $471 | $94,171201 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $307 | $74,688126 claims |
| PfizerEliquis | $16 | $37,99250 claims |
| Johnson & JohnsonXarelto | $12 | $9,24814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Hammond
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Charles GbadouweyMonroe$36K
- Susan GunnNew Orleans$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.